药物开发过程:提高效率和成本效益 328条(本栏目收费,不能显示细节,电话13136136841)
Oral osmotic pumps (OROS), 175 175
Orphan Drug Act, 62-63 63
Patent and Trademark Office (PTO), 61 61
Pharmaceutical industry changes in, 39-44 44
Pharmacy benefit management companies (PBMs), 64 64
Programmed electrical stimulation (PES), 23 23
Pharmacokinetically guided dose escalations (PGDE), 288 288
Pharmacokinetic/pharmacodynamic relationship, 23 23
Pharmacokinetics, 23, 262-264 264
Physiological systems modeling, 241-244 244
Portfolio analysis, 101-114 114
criteria for, 103-104 104
interpretation of, 112-114 114
complications, 101-103 103
considerations, 101-103 103
quantitative assessment of, 107-109 109
research and development, 101-114 114
Positron emission tomography (PET), 248 248
Powdered cellulose, 122 122
Preclinical studies, 220-252 252
Pregelatinized starch, 123 123
Prescription Drug User Fee Act of 1992, 59 59